Radcliffe Capital Management’s Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares FLAC Stock Holding History

Radcliffe Capital Management’s Portfolio FLAC Stock Details FLAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-391,501	Closed	-$3.9M	–	1136
2022 Q3	$3.9M	Buy	391,501 +52,523	+15%	+$521K	0.09%	376
2022 Q2	$3.35M	Buy	338,978 +1,501	+0.4%	+$14.8K	0.08%	450
2022 Q1	$3.32M	Buy	337,477 +87,477	+35%	+$857K	0.08%	414
2021 Q4	$2.44M	Hold	250,000	–	–	0.06%	485
2021 Q3	$2.45M	Hold	250,000	–	–	0.07%	404
2021 Q2	$2.44M	Hold	250,000	–	–	0.08%	412
2021 Q1	$2.49M	Buy	+250,000	New	+$2.55M	0.1%	357

Radcliffe Capital Management's FLAC Position: Q4 2022 in Review

Radcliffe Capital Management sold out of Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares (FLAC) in Q4 2022, closing a stake of 391,501 shares — an estimated $3.9M sold.

Radcliffe Capital Management first reported a position in FLAC in Q1 2021 and held it in 7 quarters. The position peaked at $3.9M in Q3 2022. 0 funds tracked by Wall St. Rank hold FLAC as of Q4 2022.

Radcliffe Capital Management reported no remaining Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Radcliffe Capital Management sold 391,501 Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares shares in Q4 2022, an estimated $3.9M.
Radcliffe Capital Management first reported a position in Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares in Q1 2021 and held it in 7 quarters.
Radcliffe Capital Management's Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position peaked at $3.9M in Q3 2022.
0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares as of Q4 2022.

Based on Radcliffe Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.